Market Cap 624.26B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.51
Forward PE 22.74
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 3,291,069
Avg Vol 8,194,836
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 93%
Beta 0.24
Analysts Strong Sell
Price Target $260.04

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
DoubleUpwithChuck
DoubleUpwithChuck Jul. 8 at 3:45 PM
$ELTP it is low. I think people think Oatsc stocks don’t file financials on time. $ELTP has never not filed on time. They are very consistent. $LLY $TEVA $JNJ
1 · Reply
GeniusintheFlesh
GeniusintheFlesh Jul. 8 at 3:40 PM
$ELTP $PFE $JNJ $MRNA $GME ELTP is an Epstein-Trump pe do supporter stock? That is highly disappointing. Don't get suckered by this, the pe do prez just cashed billions in crypto from his supporters. Don't become another one of this adjucated ra pists victims!
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 3:07 PM
0 · Reply
IN0V8
IN0V8 Jul. 8 at 3:06 PM
$JNJ Buy Citigroup raises target price to $298 from $285
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 3:01 PM
$JNJ $TSLA Is it JNJ? or other Big Pharma with a buyout or partnership ?
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 2:35 PM
$ELTP $PFE $JNJ $MRNA $GME Who gets in First??????? I know Roaring Kitty is in....... Elite Pharmaceuticals' (OTCMKTS: ELTP) proprietary SequestOx technology is an investigational abuse-deterrent opioid. The immediate-release oxycodone market alone is an estimated $800 million annually, giving the technology immense blockbuster financial potential if it gains the required FDA approval.SequestOx is not yet commercially available, but the financial scale and details regarding the drug and company's revenue outline why its development is so closely watched by investors:
0 · Reply
TraderDaKing
TraderDaKing Jul. 8 at 1:46 PM
$ELTP $JNJ $PFE $GME Elite’s massive 77% revenue jump to $148.9 million in fiscal year 2026 was driven by its booming generic portfolio:Generic Vyvanse (Lisdexamfetamine): This commercial launch was the single largest catalyst for the record-breaking year, capturing a substantial double-digit market share.Nostrum Asset Acquisition: ELTP recently commercialized its newly acquired Methadone Hydrochloride tablets, further widening its commercial pain-management footprint.The $20 Billion Pipeline: As highlighted on the ELTP Reddit Board, retail bulls are now focused on Elite's ongoing pivotal bioequivalence studies targeting heavy-hitting drugs like Januvia, Xeljanz, Ibrance, and Xtandi.
1 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 12:01 PM
$ELTP $PFE $JNJ $MRNA They will merger or partner with us because or Abuse-Deterrent Technology. Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule that contains an agonist in addition to naltrexone, an antagonist, used primarily in the management of alcohol dependence and drug dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the agonist releases over time, providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to the same receptors in the brain as the agonist, thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of drugs used today in pain management.
1 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 9:13 AM
$JNJ approaching first target of 271.37 in expected rally within 6.22.2026 low It should see more upside up to 305.2, while dips remain supported in 3. 7 or 11 swings within May-2026 sequence as bull run. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave
0 · Reply
theoptionsplug
theoptionsplug Jul. 8 at 6:11 AM
THINGS TO WATCH, WEDNESDAY, 7/8/2026 👁️ $LEVI $HELE $JNJ $AVAV $SPY
0 · Reply
Latest News on JNJ
Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 6 weeks ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads


DoubleUpwithChuck
DoubleUpwithChuck Jul. 8 at 3:45 PM
$ELTP it is low. I think people think Oatsc stocks don’t file financials on time. $ELTP has never not filed on time. They are very consistent. $LLY $TEVA $JNJ
1 · Reply
GeniusintheFlesh
GeniusintheFlesh Jul. 8 at 3:40 PM
$ELTP $PFE $JNJ $MRNA $GME ELTP is an Epstein-Trump pe do supporter stock? That is highly disappointing. Don't get suckered by this, the pe do prez just cashed billions in crypto from his supporters. Don't become another one of this adjucated ra pists victims!
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 3:07 PM
0 · Reply
IN0V8
IN0V8 Jul. 8 at 3:06 PM
$JNJ Buy Citigroup raises target price to $298 from $285
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 3:01 PM
$JNJ $TSLA Is it JNJ? or other Big Pharma with a buyout or partnership ?
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 2:35 PM
$ELTP $PFE $JNJ $MRNA $GME Who gets in First??????? I know Roaring Kitty is in....... Elite Pharmaceuticals' (OTCMKTS: ELTP) proprietary SequestOx technology is an investigational abuse-deterrent opioid. The immediate-release oxycodone market alone is an estimated $800 million annually, giving the technology immense blockbuster financial potential if it gains the required FDA approval.SequestOx is not yet commercially available, but the financial scale and details regarding the drug and company's revenue outline why its development is so closely watched by investors:
0 · Reply
TraderDaKing
TraderDaKing Jul. 8 at 1:46 PM
$ELTP $JNJ $PFE $GME Elite’s massive 77% revenue jump to $148.9 million in fiscal year 2026 was driven by its booming generic portfolio:Generic Vyvanse (Lisdexamfetamine): This commercial launch was the single largest catalyst for the record-breaking year, capturing a substantial double-digit market share.Nostrum Asset Acquisition: ELTP recently commercialized its newly acquired Methadone Hydrochloride tablets, further widening its commercial pain-management footprint.The $20 Billion Pipeline: As highlighted on the ELTP Reddit Board, retail bulls are now focused on Elite's ongoing pivotal bioequivalence studies targeting heavy-hitting drugs like Januvia, Xeljanz, Ibrance, and Xtandi.
1 · Reply
BarkingPuppy
BarkingPuppy Jul. 8 at 12:01 PM
$ELTP $PFE $JNJ $MRNA They will merger or partner with us because or Abuse-Deterrent Technology. Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule that contains an agonist in addition to naltrexone, an antagonist, used primarily in the management of alcohol dependence and drug dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the agonist releases over time, providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to the same receptors in the brain as the agonist, thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of drugs used today in pain management.
1 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 9:13 AM
$JNJ approaching first target of 271.37 in expected rally within 6.22.2026 low It should see more upside up to 305.2, while dips remain supported in 3. 7 or 11 swings within May-2026 sequence as bull run. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave
0 · Reply
theoptionsplug
theoptionsplug Jul. 8 at 6:11 AM
THINGS TO WATCH, WEDNESDAY, 7/8/2026 👁️ $LEVI $HELE $JNJ $AVAV $SPY
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 2:27 AM
$JNJ Current Stock Price: $267.28 Contracts to trade: $267.5 JNJ Jul 10 2026 Call Entry: $2.62 Exit: $3.65 ROI: 39% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 8 at 1:22 AM
$JNJ continue rally targeting 271.4 - 305.3 area against 6.23.2026 low It is bullish in daily & expect rally within January-2025 low to continue against May-2026 low. Short term pullback in 3, 7 or 11 swings remain supported. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
Onestockatatime20
Onestockatatime20 Jul. 7 at 10:54 PM
0 · Reply
Quantumup
Quantumup Jul. 7 at 8:59 PM
Stifel⬆️ $CMPS to $21 from $14,⬆️peak gross revenue to $1.5B and reiterated Buy -- Sees room for multiple winners—expects substantial patient demand for '360. $DFTX $JNJ HELP Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2074598446774788361?s=20
0 · Reply
TalkMarkets
TalkMarkets Jul. 7 at 8:32 PM
Unusual Put Option Activity In #JohnsonJohnson After JNJ Stock's Recent Runup $JNJ https://talkmarkets.com/article/unusual-put-option-activity-in-johnson-johnson-after-jnj-stocks-recent-runup-1783456297
0 · Reply
EquityClock
EquityClock Jul. 7 at 6:17 PM
Nice move in Pharmaceutical stocks today, an Accumulate candidate in our work. The industry is within its optimal holding period that runs between May and September. $IHE $PFE $LLY $JNJ
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 5:32 PM
$JNJ Where was Cramer @ $90-$100 ?? lol Now he tels peoples to buy here... because it's so "cheap" lol
0 · Reply
Quantumup
Quantumup Jul. 7 at 5:12 PM
BTIG⬆️ $CMPS to $25 from $14, reitd Buy/said suicide was bound to happen=part of the TRD landscape/that unfortunate reality was also driven home by today's readout—doesn't view this event as more than headline noise considering what was seen w/ Spravato. $JNJ $HELP DFTX Here's what BTIG had to say: https://x.com/Quantumup1/status/2074541548759322998?s=20
0 · Reply
Quantumup
Quantumup Jul. 7 at 4:46 PM
Oppenheimer reiterated $CMPS Outperform-$20 and said—We view the Ph3 COMP006 26-week data as reinforcing the durable efficacy profile of COMP360 (psilocybin), representing a transformative approach for the ~4M addressable TRD patients. $JNJ $DFTX HELP Here's what else Oppenheimer had to say: https://x.com/Quantumup1/status/2074535133391044982?s=20
0 · Reply
23ChaseColeman23
23ChaseColeman23 Jul. 7 at 4:41 PM
$TLT Bob seechan says The real diversified in portfolios are $KO $MCD $JNJ $WMT Not 20-30 year fixed income treasury government bonds
0 · Reply
CedarPark
CedarPark Jul. 7 at 4:26 PM
$TGTX Welp we are over the all-time highs now... SOoooo that means every short seller is under water and losing his backside. Margin calls and forced short covering on the way. $JNJ, $LLY, etc on the way to buy this..
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 7 at 3:37 PM
$TGTX With patent cliff issues and competition, BIG PHARMA keeping its money in the bank will not ensure its success and prosperity. Regarding TGTX, the BP with leadership that has vision, creativity, and willingness to act will be victorious. The other shareholders could then be saying to their leadership time is money and – How the heck did you miss that which was right before our and - most importantly - your eyes! $ABBV $JNJ $BMY
0 · Reply